GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%

GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion.

GSK Plc stock dropped on the announcement, a typical market reaction to large-premium acquisitions as investors weighed the price tag against the pipeline value. The deal adds two FDA-reviewed lung cancer drugs and positions GSK to hit its revenue target of more than £40 billion by 2031. 

What GSK Is Buying: Two Drugs, One Platform

GSK is acquiring three lung cancer assets through Nuvalent: zidesamtinib, a ROS1-positive non-small cell lung cancer drug; neladalkib, an ALK-positive NSCLC inhibitor; and a HER2 inhibitor with a broader precision oncology pipeline. Both lead drugs are currently under FDA review.

FDA Review Timelines and Revenue Potential

• Zidesamtinib carries an FDA PDUFA action date of September 18, 2026, for ROS1-positive non-small cell lung cancer patients. 
• Neladalkib’s FDA review carries a deadline of November 27, 2026, targeting ALK-positive NSCLC patients previously treated with tyrosine kinase inhibitors. 
• CGS International analysts estimate neladalkib and zidesamtinib could generate combined annual revenues of $823 million in fiscal year 2029. 
• Analyst consensus projects combined peak sales of $5.4 billion by 2035: $3.5 billion from neladalkib and $1.9 billion from zidesamtinib. 
• The deal also provides a commercial platform for GSK’s experimental B7-H3 antibody-drug conjugate Ris-Rez, currently in late-stage testing.

Why GSK Plc Needs This Deal Now

GSK CEO Luke Miels faces a hard deadline: the 2028 patent expiry of dolutegravir, the company’s best-selling HIV medicine, which currently anchors a significant portion of revenue. The Nuvalent acquisition is the direct counter-move.

GSK reported turnover growth of 4% to £32.7 billion in 2025, with 6% growth in the final quarter. The deal is expected to add to sales and operating profit in 2027. This also lift core earnings per share in 2029. 

GSK Plc Stock Reaction and Market Context

GSK’s most recent analyst rating is a Hold with a £19.00 price target, and its market cap stands at approximately $101.54 billion. The stock’s decline on acquisition day reflects standard market pricing of deal premium risk, not fundamental concern. Total biopharma M&A value in 2026 is on pace to exceed $250 billion. This is according to a Stifel note from April placing the Nuvalent deal squarely within the sector’s largest dealmaking year in recent history.

Key Takeaways

• GSK Plc agreed to buy Nuvalent for $10.6 billion at $124 per share, a 40% premium
• Net investment after cash acquired stands at $9.4 billion
• Zidesamtinib FDA decision due September 18, 2026; neladalkib deadline November 27, 2026
• Combined 2029 revenue estimate: $823 million; 2035 peak sales consensus: $5.4 billion
• Deal accretive to revenue in 2027 and core EPS in 2029
• GSK targets annual sales above £40 billion by 2031

GSK Plc’s Nuvalent deal is a direct answer to the 2028 patent cliff: two FDA-tracked lung cancer drugs, one precision oncology platform, and a clear revenue bridge from 2027 onward. Full deal terms are available at gsk.com.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.